Kevin Allan
About Kevin Allan
Kevin Allan is the Senior Director of Drug Substance Development & Manufacturing at BridgeBio, where he has worked since 2023. He has extensive experience in process development and has held various research positions at institutions such as Gilead Sciences and the University of Chicago.
Current Role at BridgeBio
Kevin Allan serves as the Senior Director of Drug Substance Development & Manufacturing at BridgeBio. He has held this position since 2023, contributing to the company's efforts in drug development. In this role, he leads the CMC Drug Substance initiatives for BridgeBio's subsidiaries, Eidos Therapeutics and Calcilytix Therapeutics. His responsibilities include overseeing the development and manufacturing processes critical to the production of drug substances.
Previous Experience at BridgeBio
Before his current role, Kevin Allan worked at BridgeBio as the Director of Drug Substance Development & Manufacturing from 2021 to 2023. During this time, he focused on enhancing the drug substance development processes and ensuring the efficient manufacturing of drug products. His experience at BridgeBio has been instrumental in shaping the company's approach to drug development.
Education and Expertise
Kevin Allan earned his Ph.D. in Chemistry from the California Institute of Technology (Caltech) between 2004 and 2010. He also holds a Bachelor of Science degree in Chemistry from the University of California, Berkeley, which he completed from 2000 to 2004. His academic background provides a strong foundation for his expertise in process development, particularly in drug substance development and manufacturing.
Career at Gilead Sciences
Kevin Allan held several positions at Gilead Sciences, where he worked from 2012 to 2021. He began as a Research Scientist I and progressed to Research Scientist II, and later served as Associate Director/Senior Research Scientist II. His tenure at Gilead included a focus on research and development in the pharmaceutical sector, contributing to various projects that advanced the company's drug development capabilities.
Postdoctoral Research at University of Chicago
From 2010 to 2012, Kevin Allan worked as a Postdoctoral Research Assistant at the University of Chicago. This position allowed him to further develop his research skills and contribute to scientific advancements in chemistry, building on the knowledge gained during his doctoral studies.